Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FS-1502 in HER2-positive advanced gastric/GEJ cancer
CTR20220633Phase 2Completed
- Sponsor
- Fosun Pharma
- Start
- Mar 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of caxmotabart entudotin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Fosun Pharma. Started Mar 2022; status: completed.
02
Drugs
caxmotabart entudotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20220633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220633.